Search 

Created in 1981, Galderma is a joint venture between Nestlé and L'Oréal.

Galderma is a global leading pharmaceutical company specializing in the research, development and marketing of innovative medical solutions in dermatology. Galderma’s important investments in R&D, extensive product portfolio, global presence and expertise in three key segments (prescription drugs, over-the-counter drugs and aesthetic and corrective solutions) contribute to maintaining its strong leadership in dermatology.

Galderma is interested in acquiring or in-licensing products for corrective dermatology and for the treatment of acne, rosacea, onychomycosis, psoriasis, seborrheic dermatitis, atopic dermatitis, other inflammatory dermatoses, non-melanoma skin cancer, viral warts, and pigmentary disorders.

COMPANY PRESCRIPTION;

Kissei America, Inc is the US subsidiary of Kissei Pharma, one of the Japanese medium-sized pharma companies spending about 20% of revenue to its R&D effort. 

 Kissei is actively seeking for in-licensing, out-licensing and other business development opportunities for new drugs. 

For in-licensing, Kissei's primary focus is the territory of Japan and the therapeutic fields of urology, dialysis management/kidney disease, women's health, opthalmology and certain diseases with unmet medical needs.

For out-licensing, Kissei is actively seeking partners for several new chemical entities for the territory outside Japan.   Such out-licensing opportunities include agents for endometriosis/fibroid, diabetes, Parkinson's disease, gout/hyperuricemia and kidney stone in various stage of development.

PIPELINE PRODUCT;

1.       NAME ; Mitiglinide

DESCRIPTION     ; Mitiglinide is a short-acting insulin secretagogue for type II diabetes.  The  

                               agent has been already on the market in Japan and some Asian countries. 

                               The product is available for licensing in certain countries outside Asian

                                countries.

PHASE                    ; Market

INDICATION        ; Type II diabetes

2.       NAME ; Remoglifozin

DESCRIPTION     ; Remogliflozin is an SGLT2 inhibitor available for licensing in certain

                                countries.

PHASE                    ; Phase ll, lla, llb

INDICATION       ; Diabetes

3.       NAME; KUL-7211

DESCRIPTION     ; KUL-7211 is a beta 2/3 dual agonist, targeting the facilitation of kidney   

                                stone passage, available for licensing.

PHASE                   ;  Phase ll, lla, llb

INDICATION       ;  Kidney Stone

4.       NAME ; KLH-2109

DESCRIPTION         ; KLH-2109 is on oral GnRH antanogist available for licensing

PHASE                       ; Phase ll, lla, llb

INDICATION           ; Endometriosis, Uterine Fibroids

5.       NAME ; KGA-3235

DESCRIPTION         ; KGA-3235 is an SGLT1 inhibitor available for licensing in certain Asian

                                    countries.

PHASE                       ; Phase l

INDICATION           ;  Diabetes

6.       NAME ; KOM-1962

DESCRIPTION         ; KOM-1962 is a novel and improved COMT inhibitor available for

                                    licensing.

PHASE                       ; Preclinical

INDICATION           ; Parkinson’s Disease

7.       NAME ; KUX-0511

DESCRIPTION         ; KUX-0511 is the agent to be developed for gout and hyperuricemia

                                    through  decreasing  formation of uric acid and uricosuric effect, and                      

                                    available for  licensing.

PHASE                       ; Phase l

INDICATION           ; Gout and Hyperuricemia

Kowa Company, Ltd is a privately-held Japanese corporation headquartered in Nagoya. Since its establishment as a textile wholesaler in 1894, Kowa has grown into a multinational company with 48 affiliates around the world and has built a strong position in developing, manufacturing, marketing and trading products within a variety of businesses. Kowa started its pharmaceutical business in 1947, and has since built a strong presence in the Japanese prescription and OTC drug markets and it is growing rapidly overseas.

Areas of Interest

•      Cardiovascular

•      Metabolic Syndromes

•      Pain Management

•      Auto-inflammatory

•      Gastroenterological

Partnership Structures

•      Co-development

•      Co-commercialization

•      Licensing

•      Across all stages of development & commercialization

Laureate Biopharma is a leader in biopharmaceutical contract development and manufacturing with more than 30 years of experience. Our scientists are expert in process development and cGMP production of therapeutic proteins, including monoclonal antibodies and Fc-fusion proteins. In addition, our portfolio of services includes aseptic filling, cell line development, analytical and stability testing, and full regulatory support. Laureate has served a global client base from its Princeton, New Jersey facility since 1981. Laureate is a portfolio company of Saints Capital, LLC.

Mallinckrodt, the pharmaceuticals business of Covidien, is a vertically integrated leader in providing products used in diagnostic procedures and in the treatment of pain and related conditions.  Covidien announced last December that they are spinning off Mallinckrodt into a stand-alone company, a process that is expected to be completed in mid-2013.  Mallinckrodt is the largest US supplier, by prescription, of opioid pain medications and a leading manufacturer of active pharmaceutical ingredients. It is also the largest US supplier of the medical isotope technetium-99m and an industry leader in radiopharmaceuticals and contrast media and delivery systems.  Sales in 2011 were $2.0 billion. Please visit www. mallinckrodt.com to learn more about our business.  The company’s branded pharmaceuticals portfolio includes EXALGO® (hydromorphone HCl) Extended-Release Tablets (CII) and PENNSAID® (diclofenac sodium topical solution) 1.5% w/w.  In June 2012, Mallinckrodt entered into agreements with Horizon Pharma and Zogenix Inc. to co-promote their branded pharmaceuticals for rheumatoid arthritis and acute migraine, respectively.  In August 2012, the FDA approved the 32 mg tablet strength of EXALGO® (hydromorphone HCI) Extended-Release Tablets (CII).  Mallinckrodt is primarily pursuing acquisition or licensing deals for pharmaceuticals which are either in late stage development or are approved for commercialization.

Meda is a global specialty pharma company with products in over 120 countries worldwide and $1.9BUSD in sales.

Meda's primary growth strategy is search and acquire focusing on acquisitions aligned with our current verticals (allergy/respiratory; women and men's health; dermatology (EU); cardiovascular (EU); and pain and inflammation).

We tend towards low risk investments, hence, late stage products (e.g., successful completion of a Phase III) or marketed products. We avoid 505(b)(2) products unless there is a clear unmet need that is met by a highly differentiated product.